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Targeting the tyrosine kinase KIT in gastrointestinal stromal tumors has led to improved treatment. Other kinases might serve
as therapeutic targets in the more common forms of sarcoma. The kinase Mirk/dyrk1B is highly expressed in the vast majority
of osteosarcomas and rhabdomyosarcomas and mediates their growth, as depletion of Mirk led to tumor cell apoptosis. Mirk is
known to increase the expression of a series of antioxidant genes, which scavenge reactive oxygen species (ROS) within various
tumor cells, mediating their survival. As a result, depleting Mirk led to increased levels of damaging ROS. Tumor cells depleted of
Mirk were also sensitized to low levels of chemotherapeutic drugs that increase ROS levels. In contrast, Mirk expression is quite
lowinmostnormalcells, andMirk depletion orembryonicknockoutofMirk did notdetectably aﬀect cell survival.Thus targeting
Mirk for intervention in sarcomas might spare most normaltissues.
1.Introduction
Targeting of cellular kinases has proved eﬃcacious for the
treatment of various cancers. Kinases are a good target for
therapy because they are readily inhibited by small, cell
permeable molecules that block their ATP-binding site and
because they act catalytically, and so they are in relatively
low abundance compared to structural elements within a
cell. In gastrointestinal stromal tumors (GISTs), the use of
inhibitors of the stem cell factor receptor kinase, KIT has
dramatically impacted treatment (reviewed in [1, 2]. The
tyrosine kinase KIT is expressed in more than 95% of GISTs,
with many exhibiting mutations that increase kinase activity.
TheKitinhibitors imatiniband sunitinibhaveinducedstable
disease orpartial responses in many patients,increasing their
length of survival. While GISTs represent only about 5% of
all sarcomas, the eﬃcacy of treatment with KIT kinase small-
moleculeinhibitorssuggeststhatotherkinasesmayrepresent
targets in more prevalent sarcomas.
Mirk/Dyrk1B is a member of the Minibrain/dyrk family
of serine-threonine kinases [3–5]. Mirk is expressed at very
low levels in most normal tissues [6]. However, Mirk is
highly expressed in normal skeletal muscle and in C2C12
myoblasts where it mediates diﬀerentiation and survival.
Mirk aids in the diﬀerentiation of skeletal muscle [7]a n d
maintains the survival of diﬀerentiating myoblasts [8]. Mirk
is not an essential gene because embryonic knockout of
Mirk/dyrk1B caused no evident phenotype in mice [9].
Likewise, normal diploid ﬁbroblasts exhibited no alteration
in survival after 20-fold depletion of Mirk [10], suggesting
that targeting Mirk for intervention might induce a selective
killing of tumor cells.
2.Mirk inOsteosarcomas
Osteosarcoma is the most common malignant bone tumor
and is highly metastatic. After chemotherapy, the tumor
recurs in about one-third of patients and the life expectancy
after recurrence is less than one year [11, 12]. Cytoplas-
mic kinases and growth factor receptor kinases have been
implicated in sarcoma survival including mTOR [13, 14],
PDGFR-A [15], and the IGFR1 [16, 17]. Recently an RNA
interference screen of the osteosarcoma cell line KHOS
was performed using a lentiviral short hairpin RNA library
targeting 673 human kinase genes [18] .T h eM i r kg e n ew a s
found by this screen to mediate sarcoma cell proliferation
and apoptosis, while a Mirk cDNA rescue assay conﬁrmed
that the identiﬁcation of Mirk was not due to oﬀ-target
eﬀects. Mirk knockdown by shRNA or by synthetic RNAi2 Sarcoma
duplexes induced apoptosis in each of 3 osteosarcoma lines
tested as well as an osteosarcoma in primary culture. No
eﬀect was seen on a benign osteoblast cell line. Mirk
protein was widely expressed in this cancer, being found
in each of 58 osteosarcomas in a tissue microarray. Most
signiﬁcantly, Kaplan-Meier analysis showed that patients
whose tumors expressed the highest amount of Mirk protein
had signiﬁcantly worse prognosis than those with low Mirk
expression. For this analysis, patients were stratiﬁed into
two groups, those alive up to 60 months after followup and
those deceased. The nonsurvivors had more Mirk in their
osteosarcomas, with P = .0012. This report [18]i n d i c a t e d
thatthekinaseMirk was essential forthegrowthand survival
ofosteosarcoma cells and that high Mirk protein levelsin the
cancer were a biomarker for tumor progression.
3.Mirk inRhabdomyosarcomas
Rhabdomyosarcomaisthemostcommonsofttissuesarcoma
in children and is diﬃcult to treat if the primary tumor
is nonresectable or if the disease presents with metastases
[19, 20]. There are two major histological types, embryonal
and alveolar. Alveolar histology is associated with a signiﬁ-
cantly worse prognosis with a ﬁve-year survival rate of less
than 30%. The precise etiology of rhabdomyosarcoma is
unknown, but it has been suggested to arise in “satellite”
cells, the committed skeletal muscle precursor cells [19].
Mirk/Dyrk1B was expressed to some extent in each of 16
clinical cases of human rhabdomyosarcoma examined [21]
and in myoblast satellite cells [7]. Furthermore, Mirk was
found to be an active kinase in each of 3 rhabdomyosar-
coma cell lines tested [21]. In addition, Mirk depletion by
synthetic RNAi duplexes induced apoptosis in each of two
rhabdomyosarcoma cell lines assayed as shown by increase
in both the apoptotic marker Annexin V and DNA breaks
revealed by TUNEL staining. Increased apoptosis led to a 3-
4-fold decrease in clonogenicity. Thus depleting Mirk led to
death of the most aggressive rhabdomyosarcoma cells.
4.Mirk inSkeletalMuscleMyoblasts
Someinsight intothepossibleroleofMirk inrhabdomyosar-
coma can be derived from studies of Mirk in skeletal muscle
myoblasts. Mirk was expressed in skeletal muscle satellite
cells in primary culture and was upregulated about 10-
fold when the satellite cells were induced to diﬀerentiate,
while knockdown of endogenous Mirk by RNA interference
blocked myoblast diﬀerentiation [7]. Mirk is activated by
the stress-activated MAP kinase kinase MKK3 [22]. These
results together imply a role for Mirk in the response to
cellular injury. Skeletal muscle is regenerated after injury by
activation of quiescent satellite cells that enter the cell cycle
and then diﬀerentiate and fuse with uninjured muscle ﬁbers
to repair the damage. Mirk may play some role in muscle
regeneration because Mirk is a stress-activated kinase that
modulates the activation of the myogenic regulatory factors
MEF2 and myogenin, which subsequently mediate myoblast
diﬀerentiation[8]. Mirk is less likely to play a signiﬁcant role
in embryonic muscle development because a Mirk/Dyrk1B
knockout mouse survived to 18 days after conceptionduring
which time skeletal muscles were developed [9]. Thus
Mirk/Dyrk1B may be a survival factor in skeletal myoblasts
undergoing repair.
5.InactivationofROSMayBetheMirk
Survival FunctioninSarcomas
The Mirk kinase gene has been localized to the 19q13
amplicon [6] and is ampliﬁed in a subset of pancreatic
cancers and ovarian cancers, and less frequently in colon
cancers [23–25]. Mirk mediates survival of these cancers
at least in part by reducing reactive oxygen species (ROS).
ROS are oxygen-containing chemical species with reactive
chemical properties,such as hydroxyl radicals,which contain
an unpaired electron and the free radical superoxide. Cancer
cells often exhibit higher levels of ROS than normal cells
because of increased metabolism and oncogenic stimulation,
and so they are under increased oxidative stress. Genes
which detoxify superoxide (superoxide dismutases 2 and
3) and which prevent the generation of hydroxyl radical
(ferroxidase/ceruloplasmin) were found to be upregulated
in SU86.86 pancreatic cancer cells [26]a n di ne a c ho f
four ovarian cancer cell lines [27] through Mirk. These
genes work together to reduce ROS. Superoxide dismutases
detoxify superoxide resulting in hydrogen peroxide, which
in turn can be metabolized either to water or to hydroxyl
radical through the Fenton reaction if Fe++ is available.
Conversion to hydroxyl radical is blocked by ferroxidase
that converts Fe++ to Fe+++. Mirk is a coactivator for
several transcription factors and increases the expression of
these antioxidant genes [26]. Thus these Mirk-upregulated
genes working together increase antioxidant potential while
minimizing hydroxyl production.
6.ROS inSkeletalMuscle
ROSare toxictocells,decreasing theirviability; soROSlevels
andcellviabilityfellfollowingdepletionofMirk fromC2C12
myoblasts and from cancer cells. Using immunoﬂuorescence
techniques, we have found that Mirk is localized in fast
twitch skeletal muscles (Mercer and Friedman, manuscript
in preparation). Such muscle endogenously produces ROS
in response to repeated contractions. Hydrogen peroxide
is produced in contracting muscle, breaking down to ROS
species, which can have diverse eﬀects on myoblasts, such as
inducingmitochondrial fragmentation [28].ROSgeneration
within single intact muscle ﬁbers was cytosolic, with a role
for NADPH oxidase-derived ROS during contractile activity
[29]. Depletion of Mirk from C2C12 myoblasts also led to
an increase in ROS (Deng and Friedman, manuscript in
preparation), consistent with ROS control being a major
role of Mirk in muscle development and function. This
protective ROS-decreasing role is likely to have provided a
selective pressure to maintain elevated Mirk levels in skeletal
muscleandtofurtherupregulateMirk expression insarcoma
cells. Thus we hypothesize that Mirk mediates sarcoma cellSarcoma 3
survival through an increase of its original function in
skeletal muscle cells, depletion of ROS.
7.MirkDepletion/InactivationPotentiates
CertainChemotherapeuticDrugs
The chemotherapeutic drug cisplatin is one of many known
to increase intracellular levels of toxic reactive oxygen
species. Thus, an increase in cisplatin toxicity selectively
in cancer cells could result from further increasing the
cisplatin-elevated ROS levels by targeting antioxidant genes
upregulated in cancers such as those mediated by the kinase
Mirk/dyrk1B. This possibility was tested, and depletion of
Mirk increased cellular ROS levels in each of 4 ovarian
cancer cell lines. Mirk depletion averaged only about 4-fold,
yet combined with cisplatin treatment enabled low levels of
drug to increase ROS to toxic levels in both SKOV3 and
TOV21G ovarian cancer cells [27]. Lowering ROS levels by
treatment with N-acetyl cysteine limited cisplatin toxicity,
resulting in higher cell numbers and decreased cleavage of
the apoptotic proteins PARP and caspase 3. Targeting Mirk
in sarcomas could increase their response to lower levels
of chemotherapeutic drugs, potentially reducing side eﬀects,
which often limit therapeutic options in these cancers.
8.HedgehogSignaling inSarcomas
Mirk/dyrk1B and Dyrk1A are about 94% identical/homol-
ogous within their conserved kinase domains, but unlike
within their unique N and C termini. The kinase domain
similarity has led many to suspect some common functions
between Dyrk1A and Mirk/dyrk1B. Dyrk1A, as one of
the Down Syndrome conserved genes, has been intensively
investigated. The essential embryonic signaling pathway,
Hedgehog, has been implicated in many cancers such as
pancreas, lung, and prostate, and Gli1 is a target of this path-
way.IninitialstudiesDyrk1AenhancedGli1-dependentgene
transcription and acted synergistically with Sonic hedgehog
to induce transcription [30]. However, the involvement of
Mirk in Hedgehog signaling is complex. Mirk is activated
by oncogenic K-ras and H-ras [10] and is an active kinase
in pancreatic cancers [31], which exhibit a very high rate of
K-ras mutation, almost 100% in advanced lesions. Mutant
K-ras signaling through Mirk/dyrk1B blocked autocrine
Hedgehog signaling to Gli1 within pancreatic cancer cells,
only allowing Hedgehog signaling to Gli1 in stromal cells,
which do not have mutant K-ras [32]. This is important
clinically because most drugs do not reach pancreatic cancer
cells because of their dense stroma [33], so the paracrine
hedgehog signaling in stromal cells can be targeted [34]
to enhance conventional chemotherapy. Activation of the
hedgehog pathway confers a poor prognosis in embryonal
and fusion gene-negative alveolar rhabdomyosarcoma [35],
and the transcription factor Gl1 is a central mediator of
EWS/FLI1 signaling in Ewing sarcoma tumors [36]. Since
Mirk was found to be an active kinase in each of 3
rhabdomyosarcoma cell lines tested [21], it may also alter
Hedgehog signaling to a paracrine mode and thus mediate
control of the stromal microenvironment of these tumors.
The WD40 repeat protein Han11 can inhibit Dyrk1A-
dependent transcription of Gli1 when Han11 also binds
the cytoskeletal regulator mDia [37]. Mirk/dyrk1B is found
in a 670 kDa complex with unknown proteins [38]. One
may be Han11, which binds to Dyrk1A, Dyrk1B/Mirk, the
related kinase HIPK2, and the mitogen-activated protein
kinase kinase kinase1 (MEKK1) [39]. When downregulated,
orconverselywhenoverexpressed,Han11altersthethreshold
and amplitude of kinase signaling by HIPK2 and MEKK1,
demonstrating a scaﬀolding function for Han11 in control-
ling these kinases in a multiprotein complex.
9.AdditionalMirk/Dyrk1B Substrates
Several other intriguing Dyrk1A substrates have been iden-
tiﬁed (CREB, STAT3, and NFAT) [40–43], and have yet
to be examined as potential Mirk substrates in sarcomas.
The STAT3 signaling pathway is constitutively activated in
each of three rhabdomyosarcoma cell lines tested, and two
small-molecule compounds inhibited both STAT3 activity
andcellproliferationandviability[44].MirkandDyrk1Aare
coactivators of FOXO1a-dependent glucose-6-phosphatase
gene expression [45], and Dyrk1A phosphorylates this
transcription factor [46]. Mirk also slightly increased the
activity of FOXO3a on a promoter-reporter construct of
the CDK inhibitor p27 [47]. The functional relevance of
these interactions is unclear. However, Mirk stabilizes p27 by
phosphorylation [48], and so it might augment this activity
by increasing p27 expression. Increased p27 levels mediate
a G0 arrest where damaged cells can repair [49]. A small-
molecule Mirk kinase inhibitor would be very useful in
conﬁrming the role of putative Mirk substrates in sarcomas.
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